PEPTIDEREPORT

Video claim watch

Benefits and Risks of Peptide Therapeutics for Physical and Mental Health

A million-view overview helped establish the current public vocabulary around peptide benefits, risks, and access.

Andrew Huberman channel1:26:41 runtime1.2M views when checked

Published Apr 1, 2024. Metadata checked Jul 12, 2026.

Watch on YouTube

Transcript review

6 material claims logged

Published with source gaps audit stateauto-captioned transcript1 operational-guidance flags1 source gap

Reviewed Jul 12, 2026. Next review Aug 12, 2026.

broad and influential, but includes direct use/dose discussion and speculative efficacy across many unapproved compounds.

auto-caption available; 18 creator chapters.

Claim-by-claim audit

What the video says, and what needs checking

00:12:06
High-risk regulatory claim

distinguishes FDA-approved, gray-market, and black-market peptides but describes sermorelin’s historical status in a way that can be mistaken for current approval.

Review topic: regulatory taxonomy.

Checked against: Compounding and the FDA: Questions and Answers

FDA Drugs@FDA and R-PEP-2; date-stamp discontinued/historical approvals.

00:27:53
Operational guidanceHigh-risk safety claim

onward includes dose and route discussion for BPC-157, despite saying it is not a recommendation.

Review topic: unapproved administration.

Checked against: FDA BPC-157 compounding safety risk: immunogenicity

Do not reproduce.

Handling: This segment contains operational guidance for an unapproved product. Peptide Report does not reproduce or endorse those instructions.

00:36:43
High-risk evidence claimHigh-risk safety claimHigh-risk regulatory claim

covers thymosin beta-4/TB-500; 00:40:49 GH/IGF-1 risks; 00:45:25 secretagogues; 01:06:12 epitalon; 01:12:09 melanotan/PT-141; 01:17:21 kisspeptin.

Review topic: multiple compounds.

Checked against: FDA BPC-157 compounding safety risk: immunogenicity

plus approved labels where applicable; never transfer evidence from parent peptide to fragment or approved indication to wellness use.

01:21:46
High-risk evidence claim

summarizes potential benefits and risks.

Review topic: category overview.

Checked against: Primary-source record still needed

Primary-source mapping pending.

Connected research

Compounds discussed

BPC-157 BPC-157 is an experimental peptide with extensive animal research but very limited human evidence. A Phase 1 registry record has no posted efficacy result, and a small uncontrolled knee-pain report does not establish benefit. It is not FDA-approved and is prohibited in sport. TB-500 TB-500 is marketed as a thymosin-beta-4-related recovery peptide. The sources currently linked to this profile are regulatory records, not human efficacy studies. It is not FDA-approved and was scheduled for FDA advisory committee discussion in July 2026. Sermorelin Sermorelin is a synthetic N-terminal fragment (1-29) of growth hormone-releasing hormone (GHRH) that was formerly FDA-approved as Geref for diagnostic use in pediatric growth hormone deficiency. The manufacturer discontinued Geref, and the product is no longer commercially available under an FDA-approved brand. It is now widely compounded by telehealth clinics for off-label anti-aging and performance use. Epitalon Epitalon is a synthetic tetrapeptide promoted for longevity and telomere-related effects. The reviewed evidence rests largely on cell studies and publications from one Russian research group. Large, independently replicated human trials have not established an anti-aging benefit.

Source check

Records used in this claim audit

PCO-02 safety and pharmacokinetics trial

ClinicalTrials.gov · Primary regulatory · Dec 22, 2015 · accessed Jul 12, 2026

Registry record for a Phase 1 safety and pharmacokinetics study associated with BPC-157. The record status is unknown and no efficacy result is posted.

6 linked pagesOpen original · clinicaltrials-bpc157-pco02